Summary

The global Influenzavirus B Infection Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Influenzavirus B Infection Drug Industry Forecast” looks at past sales and reviews total world Influenzavirus B Infection Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Influenzavirus B Infection Drug sales for 2025 through 2031. With Influenzavirus B Infection Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Influenzavirus B Infection Drug industry.
This Insight Report provides a comprehensive analysis of the global Influenzavirus B Infection Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Influenzavirus B Infection Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Influenzavirus B Infection Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Influenzavirus B Infection Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Influenzavirus B Infection Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Influenzavirus B Infection Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
APP-309
CF-403
GC-3106A
KIN-1400
Others
Segmentation by Application:
Clinic
Hospital
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AbbVie Inc
Adimmune Corp
Altravax Inc
Amarillo Biosciences Inc
Aphios Corp
BioCryst Pharmaceuticals Inc
Cadila Healthcare Ltd
ContraFect Corp
Daiichi Sankyo Company Ltd
Fujifilm Holdings Corporation
GlaxoSmithKline Plc
Green Cross Corp
Inovio Pharmaceuticals Inc
Kineta Inc
Medicago Inc
MedImmune LLC
Mucosis BV
Novavax Inc
Park Active Molecules
Romark Laboratories LC
Sanofi
Sanofi Pasteur SA
Shionogi & Co Ltd
SK Chemicals Co Ltd
TSRL Inc
Vaxart Inc
Vectura Group Plc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Influenzavirus B Infection Drug market?
What factors are driving Influenzavirus B Infection Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Influenzavirus B Infection Drug market opportunities vary by end market size?
How does Influenzavirus B Infection Drug break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Influenzavirus B Infection Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Influenzavirus B Infection Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Influenzavirus B Infection Drug by Country/Region, 2020, 2024 & 2031
2.2 Influenzavirus B Infection Drug Segment by Type
2.2.1 APP-309
2.2.2 CF-403
2.2.3 GC-3106A
2.2.4 KIN-1400
2.2.5 Others
2.3 Influenzavirus B Infection Drug Sales by Type
2.3.1 Global Influenzavirus B Infection Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Influenzavirus B Infection Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Influenzavirus B Infection Drug Sale Price by Type (2020-2025)
2.4 Influenzavirus B Infection Drug Segment by Application
2.4.1 Clinic
2.4.2 Hospital
2.4.3 Others
2.5 Influenzavirus B Infection Drug Sales by Application
2.5.1 Global Influenzavirus B Infection Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Influenzavirus B Infection Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Influenzavirus B Infection Drug Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Influenzavirus B Infection Drug Breakdown Data by Company
3.1.1 Global Influenzavirus B Infection Drug Annual Sales by Company (2020-2025)
3.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Company (2020-2025)
3.2 Global Influenzavirus B Infection Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Influenzavirus B Infection Drug Revenue by Company (2020-2025)
3.2.2 Global Influenzavirus B Infection Drug Revenue Market Share by Company (2020-2025)
3.3 Global Influenzavirus B Infection Drug Sale Price by Company
3.4 Key Manufacturers Influenzavirus B Infection Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Influenzavirus B Infection Drug Product Location Distribution
3.4.2 Players Influenzavirus B Infection Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Influenzavirus B Infection Drug by Geographic Region
4.1 World Historic Influenzavirus B Infection Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Influenzavirus B Infection Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Influenzavirus B Infection Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Influenzavirus B Infection Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Influenzavirus B Infection Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Influenzavirus B Infection Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Influenzavirus B Infection Drug Sales Growth
4.4 APAC Influenzavirus B Infection Drug Sales Growth
4.5 Europe Influenzavirus B Infection Drug Sales Growth
4.6 Middle East & Africa Influenzavirus B Infection Drug Sales Growth
5 Americas
5.1 Americas Influenzavirus B Infection Drug Sales by Country
5.1.1 Americas Influenzavirus B Infection Drug Sales by Country (2020-2025)
5.1.2 Americas Influenzavirus B Infection Drug Revenue by Country (2020-2025)
5.2 Americas Influenzavirus B Infection Drug Sales by Type (2020-2025)
5.3 Americas Influenzavirus B Infection Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Influenzavirus B Infection Drug Sales by Region
6.1.1 APAC Influenzavirus B Infection Drug Sales by Region (2020-2025)
6.1.2 APAC Influenzavirus B Infection Drug Revenue by Region (2020-2025)
6.2 APAC Influenzavirus B Infection Drug Sales by Type (2020-2025)
6.3 APAC Influenzavirus B Infection Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Influenzavirus B Infection Drug by Country
7.1.1 Europe Influenzavirus B Infection Drug Sales by Country (2020-2025)
7.1.2 Europe Influenzavirus B Infection Drug Revenue by Country (2020-2025)
7.2 Europe Influenzavirus B Infection Drug Sales by Type (2020-2025)
7.3 Europe Influenzavirus B Infection Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Influenzavirus B Infection Drug by Country
8.1.1 Middle East & Africa Influenzavirus B Infection Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Influenzavirus B Infection Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Influenzavirus B Infection Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Influenzavirus B Infection Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Influenzavirus B Infection Drug
10.3 Manufacturing Process Analysis of Influenzavirus B Infection Drug
10.4 Industry Chain Structure of Influenzavirus B Infection Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Influenzavirus B Infection Drug Distributors
11.3 Influenzavirus B Infection Drug Customer
12 World Forecast Review for Influenzavirus B Infection Drug by Geographic Region
12.1 Global Influenzavirus B Infection Drug Market Size Forecast by Region
12.1.1 Global Influenzavirus B Infection Drug Forecast by Region (2026-2031)
12.1.2 Global Influenzavirus B Infection Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Influenzavirus B Infection Drug Forecast by Type (2026-2031)
12.7 Global Influenzavirus B Infection Drug Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 AbbVie Inc
13.1.1 AbbVie Inc Company Information
13.1.2 AbbVie Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.1.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 AbbVie Inc Main Business Overview
13.1.5 AbbVie Inc Latest Developments
13.2 Adimmune Corp
13.2.1 Adimmune Corp Company Information
13.2.2 Adimmune Corp Influenzavirus B Infection Drug Product Portfolios and Specifications
13.2.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Adimmune Corp Main Business Overview
13.2.5 Adimmune Corp Latest Developments
13.3 Altravax Inc
13.3.1 Altravax Inc Company Information
13.3.2 Altravax Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.3.3 Altravax Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Altravax Inc Main Business Overview
13.3.5 Altravax Inc Latest Developments
13.4 Amarillo Biosciences Inc
13.4.1 Amarillo Biosciences Inc Company Information
13.4.2 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.4.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Amarillo Biosciences Inc Main Business Overview
13.4.5 Amarillo Biosciences Inc Latest Developments
13.5 Aphios Corp
13.5.1 Aphios Corp Company Information
13.5.2 Aphios Corp Influenzavirus B Infection Drug Product Portfolios and Specifications
13.5.3 Aphios Corp Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Aphios Corp Main Business Overview
13.5.5 Aphios Corp Latest Developments
13.6 BioCryst Pharmaceuticals Inc
13.6.1 BioCryst Pharmaceuticals Inc Company Information
13.6.2 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.6.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 BioCryst Pharmaceuticals Inc Main Business Overview
13.6.5 BioCryst Pharmaceuticals Inc Latest Developments
13.7 Cadila Healthcare Ltd
13.7.1 Cadila Healthcare Ltd Company Information
13.7.2 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolios and Specifications
13.7.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Cadila Healthcare Ltd Main Business Overview
13.7.5 Cadila Healthcare Ltd Latest Developments
13.8 ContraFect Corp
13.8.1 ContraFect Corp Company Information
13.8.2 ContraFect Corp Influenzavirus B Infection Drug Product Portfolios and Specifications
13.8.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 ContraFect Corp Main Business Overview
13.8.5 ContraFect Corp Latest Developments
13.9 Daiichi Sankyo Company Ltd
13.9.1 Daiichi Sankyo Company Ltd Company Information
13.9.2 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolios and Specifications
13.9.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Daiichi Sankyo Company Ltd Main Business Overview
13.9.5 Daiichi Sankyo Company Ltd Latest Developments
13.10 Fujifilm Holdings Corporation
13.10.1 Fujifilm Holdings Corporation Company Information
13.10.2 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolios and Specifications
13.10.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Fujifilm Holdings Corporation Main Business Overview
13.10.5 Fujifilm Holdings Corporation Latest Developments
13.11 GlaxoSmithKline Plc
13.11.1 GlaxoSmithKline Plc Company Information
13.11.2 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.11.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 GlaxoSmithKline Plc Main Business Overview
13.11.5 GlaxoSmithKline Plc Latest Developments
13.12 Green Cross Corp
13.12.1 Green Cross Corp Company Information
13.12.2 Green Cross Corp Influenzavirus B Infection Drug Product Portfolios and Specifications
13.12.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Green Cross Corp Main Business Overview
13.12.5 Green Cross Corp Latest Developments
13.13 Inovio Pharmaceuticals Inc
13.13.1 Inovio Pharmaceuticals Inc Company Information
13.13.2 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.13.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Inovio Pharmaceuticals Inc Main Business Overview
13.13.5 Inovio Pharmaceuticals Inc Latest Developments
13.14 Kineta Inc
13.14.1 Kineta Inc Company Information
13.14.2 Kineta Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.14.3 Kineta Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Kineta Inc Main Business Overview
13.14.5 Kineta Inc Latest Developments
13.15 Medicago Inc
13.15.1 Medicago Inc Company Information
13.15.2 Medicago Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.15.3 Medicago Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Medicago Inc Main Business Overview
13.15.5 Medicago Inc Latest Developments
13.16 MedImmune LLC
13.16.1 MedImmune LLC Company Information
13.16.2 MedImmune LLC Influenzavirus B Infection Drug Product Portfolios and Specifications
13.16.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 MedImmune LLC Main Business Overview
13.16.5 MedImmune LLC Latest Developments
13.17 Mucosis BV
13.17.1 Mucosis BV Company Information
13.17.2 Mucosis BV Influenzavirus B Infection Drug Product Portfolios and Specifications
13.17.3 Mucosis BV Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Mucosis BV Main Business Overview
13.17.5 Mucosis BV Latest Developments
13.18 Novavax Inc
13.18.1 Novavax Inc Company Information
13.18.2 Novavax Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.18.3 Novavax Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Novavax Inc Main Business Overview
13.18.5 Novavax Inc Latest Developments
13.19 Park Active Molecules
13.19.1 Park Active Molecules Company Information
13.19.2 Park Active Molecules Influenzavirus B Infection Drug Product Portfolios and Specifications
13.19.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Park Active Molecules Main Business Overview
13.19.5 Park Active Molecules Latest Developments
13.20 Romark Laboratories LC
13.20.1 Romark Laboratories LC Company Information
13.20.2 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolios and Specifications
13.20.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Romark Laboratories LC Main Business Overview
13.20.5 Romark Laboratories LC Latest Developments
13.21 Sanofi
13.21.1 Sanofi Company Information
13.21.2 Sanofi Influenzavirus B Infection Drug Product Portfolios and Specifications
13.21.3 Sanofi Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Sanofi Main Business Overview
13.21.5 Sanofi Latest Developments
13.22 Sanofi Pasteur SA
13.22.1 Sanofi Pasteur SA Company Information
13.22.2 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolios and Specifications
13.22.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 Sanofi Pasteur SA Main Business Overview
13.22.5 Sanofi Pasteur SA Latest Developments
13.23 Shionogi & Co Ltd
13.23.1 Shionogi & Co Ltd Company Information
13.23.2 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolios and Specifications
13.23.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.23.4 Shionogi & Co Ltd Main Business Overview
13.23.5 Shionogi & Co Ltd Latest Developments
13.24 SK Chemicals Co Ltd
13.24.1 SK Chemicals Co Ltd Company Information
13.24.2 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolios and Specifications
13.24.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.24.4 SK Chemicals Co Ltd Main Business Overview
13.24.5 SK Chemicals Co Ltd Latest Developments
13.25 TSRL Inc
13.25.1 TSRL Inc Company Information
13.25.2 TSRL Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.25.3 TSRL Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.25.4 TSRL Inc Main Business Overview
13.25.5 TSRL Inc Latest Developments
13.26 Vaxart Inc
13.26.1 Vaxart Inc Company Information
13.26.2 Vaxart Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.26.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.26.4 Vaxart Inc Main Business Overview
13.26.5 Vaxart Inc Latest Developments
13.27 Vectura Group Plc
13.27.1 Vectura Group Plc Company Information
13.27.2 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolios and Specifications
13.27.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.27.4 Vectura Group Plc Main Business Overview
13.27.5 Vectura Group Plc Latest Developments
14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Influenzavirus B Infection Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Influenzavirus B Infection Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of APP-309
Table 4. Major Players of CF-403
Table 5. Major Players of GC-3106A
Table 6. Major Players of KIN-1400
Table 7. Major Players of Others
Table 8. Global Influenzavirus B Infection Drug Sales by Type (2020-2025) & (K Pcs)
Table 9. Global Influenzavirus B Infection Drug Sales Market Share by Type (2020-2025)
Table 10. Global Influenzavirus B Infection Drug Revenue by Type (2020-2025) & ($ million)
Table 11. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2020-2025)
Table 12. Global Influenzavirus B Infection Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 13. Global Influenzavirus B Infection Drug Sale by Application (2020-2025) & (K Pcs)
Table 14. Global Influenzavirus B Infection Drug Sale Market Share by Application (2020-2025)
Table 15. Global Influenzavirus B Infection Drug Revenue by Application (2020-2025) & ($ million)
Table 16. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2020-2025)
Table 17. Global Influenzavirus B Infection Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 18. Global Influenzavirus B Infection Drug Sales by Company (2020-2025) & (K Pcs)
Table 19. Global Influenzavirus B Infection Drug Sales Market Share by Company (2020-2025)
Table 20. Global Influenzavirus B Infection Drug Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Influenzavirus B Infection Drug Revenue Market Share by Company (2020-2025)
Table 22. Global Influenzavirus B Infection Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 23. Key Manufacturers Influenzavirus B Infection Drug Producing Area Distribution and Sales Area
Table 24. Players Influenzavirus B Infection Drug Products Offered
Table 25. Influenzavirus B Infection Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Influenzavirus B Infection Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 29. Global Influenzavirus B Infection Drug Sales Market Share Geographic Region (2020-2025)
Table 30. Global Influenzavirus B Infection Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Influenzavirus B Infection Drug Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Influenzavirus B Infection Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 33. Global Influenzavirus B Infection Drug Sales Market Share by Country/Region (2020-2025)
Table 34. Global Influenzavirus B Infection Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Influenzavirus B Infection Drug Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Influenzavirus B Infection Drug Sales by Country (2020-2025) & (K Pcs)
Table 37. Americas Influenzavirus B Infection Drug Sales Market Share by Country (2020-2025)
Table 38. Americas Influenzavirus B Infection Drug Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Influenzavirus B Infection Drug Sales by Type (2020-2025) & (K Pcs)
Table 40. Americas Influenzavirus B Infection Drug Sales by Application (2020-2025) & (K Pcs)
Table 41. APAC Influenzavirus B Infection Drug Sales by Region (2020-2025) & (K Pcs)
Table 42. APAC Influenzavirus B Infection Drug Sales Market Share by Region (2020-2025)
Table 43. APAC Influenzavirus B Infection Drug Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Influenzavirus B Infection Drug Sales by Type (2020-2025) & (K Pcs)
Table 45. APAC Influenzavirus B Infection Drug Sales by Application (2020-2025) & (K Pcs)
Table 46. Europe Influenzavirus B Infection Drug Sales by Country (2020-2025) & (K Pcs)
Table 47. Europe Influenzavirus B Infection Drug Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Influenzavirus B Infection Drug Sales by Type (2020-2025) & (K Pcs)
Table 49. Europe Influenzavirus B Infection Drug Sales by Application (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Influenzavirus B Infection Drug Sales by Country (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Influenzavirus B Infection Drug Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Influenzavirus B Infection Drug Sales by Type (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Influenzavirus B Infection Drug Sales by Application (2020-2025) & (K Pcs)
Table 54. Key Market Drivers & Growth Opportunities of Influenzavirus B Infection Drug
Table 55. Key Market Challenges & Risks of Influenzavirus B Infection Drug
Table 56. Key Industry Trends of Influenzavirus B Infection Drug
Table 57. Influenzavirus B Infection Drug Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Influenzavirus B Infection Drug Distributors List
Table 60. Influenzavirus B Infection Drug Customer List
Table 61. Global Influenzavirus B Infection Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 62. Global Influenzavirus B Infection Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 63. Americas Influenzavirus B Infection Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 64. Americas Influenzavirus B Infection Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 65. APAC Influenzavirus B Infection Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 66. APAC Influenzavirus B Infection Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 67. Europe Influenzavirus B Infection Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 68. Europe Influenzavirus B Infection Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Influenzavirus B Infection Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 70. Middle East & Africa Influenzavirus B Infection Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 71. Global Influenzavirus B Infection Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 72. Global Influenzavirus B Infection Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 73. Global Influenzavirus B Infection Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 74. Global Influenzavirus B Infection Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 75. AbbVie Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 76. AbbVie Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 77. AbbVie Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. AbbVie Inc Main Business
Table 79. AbbVie Inc Latest Developments
Table 80. Adimmune Corp Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 81. Adimmune Corp Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 82. Adimmune Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83. Adimmune Corp Main Business
Table 84. Adimmune Corp Latest Developments
Table 85. Altravax Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 86. Altravax Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 87. Altravax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Altravax Inc Main Business
Table 89. Altravax Inc Latest Developments
Table 90. Amarillo Biosciences Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 91. Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 92. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. Amarillo Biosciences Inc Main Business
Table 94. Amarillo Biosciences Inc Latest Developments
Table 95. Aphios Corp Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 96. Aphios Corp Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 97. Aphios Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. Aphios Corp Main Business
Table 99. Aphios Corp Latest Developments
Table 100. BioCryst Pharmaceuticals Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 101. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 102. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 103. BioCryst Pharmaceuticals Inc Main Business
Table 104. BioCryst Pharmaceuticals Inc Latest Developments
Table 105. Cadila Healthcare Ltd Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 106. Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 107. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 108. Cadila Healthcare Ltd Main Business
Table 109. Cadila Healthcare Ltd Latest Developments
Table 110. ContraFect Corp Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 111. ContraFect Corp Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 112. ContraFect Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 113. ContraFect Corp Main Business
Table 114. ContraFect Corp Latest Developments
Table 115. Daiichi Sankyo Company Ltd Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 116. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 117. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 118. Daiichi Sankyo Company Ltd Main Business
Table 119. Daiichi Sankyo Company Ltd Latest Developments
Table 120. Fujifilm Holdings Corporation Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 121. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 122. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 123. Fujifilm Holdings Corporation Main Business
Table 124. Fujifilm Holdings Corporation Latest Developments
Table 125. GlaxoSmithKline Plc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 126. GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 127. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 128. GlaxoSmithKline Plc Main Business
Table 129. GlaxoSmithKline Plc Latest Developments
Table 130. Green Cross Corp Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 131. Green Cross Corp Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 132. Green Cross Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 133. Green Cross Corp Main Business
Table 134. Green Cross Corp Latest Developments
Table 135. Inovio Pharmaceuticals Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 136. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 137. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 138. Inovio Pharmaceuticals Inc Main Business
Table 139. Inovio Pharmaceuticals Inc Latest Developments
Table 140. Kineta Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 141. Kineta Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 142. Kineta Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 143. Kineta Inc Main Business
Table 144. Kineta Inc Latest Developments
Table 145. Medicago Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 146. Medicago Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 147. Medicago Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 148. Medicago Inc Main Business
Table 149. Medicago Inc Latest Developments
Table 150. MedImmune LLC Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 151. MedImmune LLC Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 152. MedImmune LLC Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 153. MedImmune LLC Main Business
Table 154. MedImmune LLC Latest Developments
Table 155. Mucosis BV Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 156. Mucosis BV Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 157. Mucosis BV Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 158. Mucosis BV Main Business
Table 159. Mucosis BV Latest Developments
Table 160. Novavax Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 161. Novavax Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 162. Novavax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 163. Novavax Inc Main Business
Table 164. Novavax Inc Latest Developments
Table 165. Park Active Molecules Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 166. Park Active Molecules Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 167. Park Active Molecules Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 168. Park Active Molecules Main Business
Table 169. Park Active Molecules Latest Developments
Table 170. Romark Laboratories LC Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 171. Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 172. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 173. Romark Laboratories LC Main Business
Table 174. Romark Laboratories LC Latest Developments
Table 175. Sanofi Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 176. Sanofi Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 177. Sanofi Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 178. Sanofi Main Business
Table 179. Sanofi Latest Developments
Table 180. Sanofi Pasteur SA Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 181. Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 182. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 183. Sanofi Pasteur SA Main Business
Table 184. Sanofi Pasteur SA Latest Developments
Table 185. Shionogi & Co Ltd Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 186. Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 187. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 188. Shionogi & Co Ltd Main Business
Table 189. Shionogi & Co Ltd Latest Developments
Table 190. SK Chemicals Co Ltd Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 191. SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 192. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 193. SK Chemicals Co Ltd Main Business
Table 194. SK Chemicals Co Ltd Latest Developments
Table 195. TSRL Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 196. TSRL Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 197. TSRL Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 198. TSRL Inc Main Business
Table 199. TSRL Inc Latest Developments
Table 200. Vaxart Inc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 201. Vaxart Inc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 202. Vaxart Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 203. Vaxart Inc Main Business
Table 204. Vaxart Inc Latest Developments
Table 205. Vectura Group Plc Basic Information, Influenzavirus B Infection Drug Manufacturing Base, Sales Area and Its Competitors
Table 206. Vectura Group Plc Influenzavirus B Infection Drug Product Portfolios and Specifications
Table 207. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 208. Vectura Group Plc Main Business
Table 209. Vectura Group Plc Latest Developments


List of Figures
Figure 1. Picture of Influenzavirus B Infection Drug
Figure 2. Influenzavirus B Infection Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Influenzavirus B Infection Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Influenzavirus B Infection Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Influenzavirus B Infection Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Influenzavirus B Infection Drug Sales Market Share by Country/Region (2024)
Figure 10. Influenzavirus B Infection Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of APP-309
Figure 12. Product Picture of CF-403
Figure 13. Product Picture of GC-3106A
Figure 14. Product Picture of KIN-1400
Figure 15. Product Picture of Others
Figure 16. Global Influenzavirus B Infection Drug Sales Market Share by Type in 2025
Figure 17. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2020-2025)
Figure 18. Influenzavirus B Infection Drug Consumed in Clinic
Figure 19. Global Influenzavirus B Infection Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 20. Influenzavirus B Infection Drug Consumed in Hospital
Figure 21. Global Influenzavirus B Infection Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 22. Influenzavirus B Infection Drug Consumed in Others
Figure 23. Global Influenzavirus B Infection Drug Market: Others (2020-2025) & (K Pcs)
Figure 24. Global Influenzavirus B Infection Drug Sale Market Share by Application (2024)
Figure 25. Global Influenzavirus B Infection Drug Revenue Market Share by Application in 2025
Figure 26. Influenzavirus B Infection Drug Sales by Company in 2025 (K Pcs)
Figure 27. Global Influenzavirus B Infection Drug Sales Market Share by Company in 2025
Figure 28. Influenzavirus B Infection Drug Revenue by Company in 2025 ($ millions)
Figure 29. Global Influenzavirus B Infection Drug Revenue Market Share by Company in 2025
Figure 30. Global Influenzavirus B Infection Drug Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Influenzavirus B Infection Drug Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Influenzavirus B Infection Drug Sales 2020-2025 (K Pcs)
Figure 33. Americas Influenzavirus B Infection Drug Revenue 2020-2025 ($ millions)
Figure 34. APAC Influenzavirus B Infection Drug Sales 2020-2025 (K Pcs)
Figure 35. APAC Influenzavirus B Infection Drug Revenue 2020-2025 ($ millions)
Figure 36. Europe Influenzavirus B Infection Drug Sales 2020-2025 (K Pcs)
Figure 37. Europe Influenzavirus B Infection Drug Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Influenzavirus B Infection Drug Sales 2020-2025 (K Pcs)
Figure 39. Middle East & Africa Influenzavirus B Infection Drug Revenue 2020-2025 ($ millions)
Figure 40. Americas Influenzavirus B Infection Drug Sales Market Share by Country in 2025
Figure 41. Americas Influenzavirus B Infection Drug Revenue Market Share by Country (2020-2025)
Figure 42. Americas Influenzavirus B Infection Drug Sales Market Share by Type (2020-2025)
Figure 43. Americas Influenzavirus B Infection Drug Sales Market Share by Application (2020-2025)
Figure 44. United States Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Influenzavirus B Infection Drug Sales Market Share by Region in 2025
Figure 49. APAC Influenzavirus B Infection Drug Revenue Market Share by Region (2020-2025)
Figure 50. APAC Influenzavirus B Infection Drug Sales Market Share by Type (2020-2025)
Figure 51. APAC Influenzavirus B Infection Drug Sales Market Share by Application (2020-2025)
Figure 52. China Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. India Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Influenzavirus B Infection Drug Sales Market Share by Country in 2025
Figure 60. Europe Influenzavirus B Infection Drug Revenue Market Share by Country (2020-2025)
Figure 61. Europe Influenzavirus B Infection Drug Sales Market Share by Type (2020-2025)
Figure 62. Europe Influenzavirus B Infection Drug Sales Market Share by Application (2020-2025)
Figure 63. Germany Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. France Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Influenzavirus B Infection Drug Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Influenzavirus B Infection Drug Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Influenzavirus B Infection Drug Sales Market Share by Application (2020-2025)
Figure 71. Egypt Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Influenzavirus B Infection Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Influenzavirus B Infection Drug in 2025
Figure 77. Manufacturing Process Analysis of Influenzavirus B Infection Drug
Figure 78. Industry Chain Structure of Influenzavirus B Infection Drug
Figure 79. Channels of Distribution
Figure 80. Global Influenzavirus B Infection Drug Sales Market Forecast by Region (2026-2031)
Figure 81. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Application (2026-2031)